Management of Patients on Cymbalta and Plavix

Introduction to Combination Therapy

The American Heart Association and stroke guidelines recommend careful monitoring of patients on combination therapy with antiplatelet agents like clopidogrel and serotonin-norepinephrine reuptake inhibitors like duloxetine due to increased bleeding risk 1, 2

The International Stroke Society suggests evaluating a patient's baseline bleeding risk factors, including history of gastrointestinal bleeding, peptic ulcer disease, age >75 years, renal impairment, or concurrent use of anticoagulants, when considering combination therapy with duloxetine and clopidogrel 1, 3
The American College of Cardiology recommends avoiding omeprazole or esomeprazole for gastroprotection in patients on clopidogrel due to significant CYP2C19 inhibition, and instead using pantoprazole, dexlansoprazole, or lansoprazole to maintain clopidogrel's effectiveness 3

The American Heart Association advises monitoring patients on combination therapy for signs of bleeding, such as bruising, petechiae, melena, hematemesis, hematuria, or unexplained anemia, and counseling them to report any unusual bleeding or bruising immediately 1, 2
The guideline society recommends exercising extreme caution or considering alternatives if the patient has a history of significant gastrointestinal bleeding, is taking triple therapy, is elderly with multiple comorbidities, or has impaired renal or hepatic function 1, 3

The International Stroke Society suggests that short-term dual antiplatelet therapy after minor stroke or TIA may be appropriate, but longer-term use increases bleeding and mortality risk unless there is a specific indication like a coronary stent 1, 2
The American College of Cardiology recommends discussing alternative antidepressants with less effect on platelet function if bleeding risk is particularly high, and considering the therapeutic benefit of adding duloxetine to dual antiplatelet therapy 1, 3